Kazia Therapeutics
KZIA
6 hedge funds and large institutions have $314K invested in Kazia Therapeutics in 2018 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 0 closing their positions.
0.09% more ownership
Funds ownership: 0.72% → 0.8% (+0.09%)
0% more funds holding
Funds holding: 6 → 6 (0)
41% less capital invested
Capital invested by funds: $531K → $314K (-$217K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$29.1K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$27.3K |
Top Sellers
KZIA Hedge Fund Activity: Q2 2018 in Review
6 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Kazia Therapeutics (KZIA) for Q2 2018, worth a combined $314K — down 41% from $531K a quarter earlier.
Fund positioning in KZIA was balanced in Q2 2018: 0 funds opened new positions, 0 closed out, 2 added to existing stakes and 0 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $29.1K.
- 6 institutional investors held Kazia Therapeutics (KZIA) as of Q2 2018, unchanged from Q1 2018.
- Funds reported $314K of Kazia Therapeutics stock for Q2 2018, down 41% quarter-over-quarter.
- 0 funds opened new Kazia Therapeutics positions in Q2 2018 and 0 closed out.
- The largest Kazia Therapeutics buyer in Q2 2018 was Morgan Stanley, an estimated $29.1K added.
Based on aggregated 13F filings for Q2 2018.